FDA adds a 1.7 mg adolescent dose and a severe GI warning to Wegovy

The FDA on November 27, 2024, approved a supplement to Wegovy's (semaglutide) prescribing information that adds a 1.7 mg weekly maintenance dose for adolescents ages 12 to less than 18 with obesity and creates a new Warnings and Precautions subsection covering severe gastrointestinal adverse reactions ^[1]. The change applies to Novo Nordisk's already-approved pediatric indication for Wegovy, which is used to reduce excess body weight and help maintain that weight loss long term ^[1].

Before this update, adolescents on Wegovy did not have this particular dose as a listed maintenance option. The new labeling adds 1.7 mg subcutaneously once weekly as an additional maintenance dose specifically for this age group ^[1]. The approval also adds Section 5.6, Severe Gastrointestinal Adverse Reactions, to the Warnings and Precautions section, which the FDA said brings Wegovy's labeling in line with warnings already used for other GLP-1 receptor agonist drugs ^[1]. Separately, the agency made editorial changes to the existing Acute Pancreatitis subsection to improve clarity, along with other wording and organizational updates meant to modernize the label under current guidance ^[1].

The pediatric dosing change is tied to a postmarketing requirement Novo Nordisk had to fulfill. The FDA's July 2023 approval letter had required the company to run exposure and exposure-response analyses to support the 1.7 mg dose for chronic weight management in patients ages 12 to less than 18, drawing on pharmacokinetic and pharmacodynamic data from the STEP 1, STEP TEENS, and STEP 6 trials ^[1]. In its November 2024 letter, the FDA confirmed it reviewed Novo Nordisk's January 29, 2024, submission containing the final report and concluded the requirement was fulfilled ^[1]. The agency noted that other postmarketing requirements from its June 2021 and July 2023 approval letters remain open ^[1].

The FDA also confirmed Novo Nordisk had satisfied a related pediatric study requirement under the Pediatric Research Equity Act for the 12-to-17 age group covered by this supplement ^[1]. The Medication Guide that accompanies Wegovy was updated to reflect the same changes made to the prescribing information ^[1].

Why it matters for patients

For families of adolescents using Wegovy, the label now lists an additional maintenance dose option, 1.7 mg weekly, that clinicians and patients can consider as part of ongoing treatment for chronic weight management ^[1]. The letter does not specify where 1.7 mg falls in the overall dose-escalation sequence relative to other maintenance doses, and that detail is not addressed in this source.

The new Section 5.6 warning about severe gastrointestinal adverse reactions is now a standard part of Wegovy's label, matching similar warnings that already exist for other drugs in the GLP-1 receptor agonist class ^[1]. This does not necessarily mean new safety data emerged specific to Wegovy; the FMDA's letter describes the change as one made "to align with the labeling for other GLP-1 receptor agonists" ^[1]. What specific gastrointestinal reactions prompted this alignment, and how common they are, is not detailed in this letter.

The editorial revisions to the pancreatitis warning and other label sections are described as changes meant to improve clarity and readability rather than reflecting new clinical findings ^[1].

What happens next

Novo Nordisk was required to submit the updated content of labeling in structured product labeling format within 14 days of the November 27, 2024, letter, and to submit a statement of intent to comply with promotional labeling rules within 7 days ^[1]. The company must also submit any required patent information for the Orange Book within 30 days of approval ^[1]. The FDA noted that additional postmarketing requirements from 2021 and 2023 approval letters remain open, though this source does not specify their status or deadlines ^[1].